Upon substrate binding TG2 dramatically changes its structure (Pinkas et al., PLoS Biol. 2007). By reacting TG2 with a novel irreversible inhibitor we could stabilize TG2 in the open conformation which we branded Open tTG™.
Open tTG™ – it fits the antigen to the autoantibody – is the key to detect seronegative or borderline celiac disease patients. Used as antigen in ELISA-based diagnostics, Open tTG™ (E006
) is superior to the so far used closed conformation TG2 especially for patient's sera with low or negative tTG autoantibody-titers (Lindfors et al., J. Clin. Immunol. 2011, 31:436-42).
For the purified non coated protein products
, Inhibited TG3 and Inhibited TG6 please refer to Section: Transglutaminases